Skip to content

Study of the Effect of inhaled Short Acting Beta 2 Agonist(procaterol) on Breathlessness on Exertion in COPD patients.

Study of the Effect of inhaled Short Acting Beta 2 Agonist(procaterol) on Breathlessness on Exertion in COPD patients. - Study of procaterol on Breathlessness on exertion in COPD patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007543
Enrollment
40
Registered
2012-03-22
Start date
2012-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Interventions

The usual adult dose is 20microg(2puffs)of procaterol hydrochloride hydrate. In the case of MEPTIN Kid Air use is 20microg(4puffs). The administration should be done about 15minutes before breathlessn
s age and severity of symptoms.

Sponsors

Tokyo Women's Medical University Tohoku University Hospital Wakayama Medical University Tohoku Rosai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient will be eligible for inclusion in this study if all of the following criteria are met: 1.An outpatient with COPD, but do not change the state, during study. 2.A patient without experience of airway infection or exacerbation within 3 months. 3.Patients meet the COPD guidelines of the Japanese Respiratory Society. The GOLD stages are stage >= II

Exclusion criteria

Exclusion criteria: A patient will not be eligible for inclusion in this study if any of the following criteria 1. There is a current diagnosis of asthma, in the opinion of the investigator 2. Patients with contraindication of procaterol inhalation. 3. The investigator judge to exclude

Design outcomes

Primary

MeasureTime frame
severity of Breathlessness in exertions(Shortness of Breath Questionaire)

Secondary

MeasureTime frame
Activities of Daily Living(ADL) using Actimarker

Countries

Japan

Contacts

Public ContactHiromasa Ogawa

Tohoku University school of Medicine industrial medicine

022-717-8006

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026